CINC Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 feb 2023 @ 22:00):

Stats
Dagens volum	0.00
Gjennomsnittsvolum	625 748
Markedsverdi	1.27B
EPS	$0 ( 2023-03-28 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.46
ATR14	$0.860 (2.96%)

Insider Trading

Date	Person	Action	Amount	type
2023-02-24	5am Partners Vi, Llc	Sell	496 323	Common Stock
2023-02-24	Healy James	Sell	9 803	Common Stock
2022-11-28	Healy James	Sell	6 000	Common Stock
2023-02-24	Healy James	Sell	19 608	Common Stock
2023-02-24	Healy James	Sell	6 073 949	Common Stock

INSIDER POWER
-68.81
Last 98 transactions
Buy: 39 839 974 \| Sell: 98 795 779

Volum Korrelasjon

Lang: -0.03 (neutral)

Kort: -0.86 (strong negative)

Signal:(69.258) Neutral

CinCor Pharma, Inc. Korrelasjon

10 Mest positive korrelasjoner
TCBX	0.88
ADV	0.878
SNCR	0.87
RDVT	0.869
PVBC	0.864
DWSH	0.863
ALTO	0.861
TSLA	0.854
GILT	0.85
SWIM	0.847

10 Mest negative korrelasjoner
BYFC	-0.939
STTK	-0.935
CNTY	-0.925
MBIN	-0.914
SLMBP	-0.907
DOOO	-0.905
TREE	-0.905
CASH	-0.903
TTSH	-0.902
TBBK	-0.897

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

CinCor Pharma, Inc. Korrelasjon - Valuta/Råvare

0.76
( moderate )

0.28
( neutral )

0.05
( neutral )

0.72
( moderate )

-0.25
( neutral )

-0.77
( moderate negative )

CinCor Pharma, Inc. Økonomi

Annual	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1 422.09

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1 422.09

FY	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.950

FY	2019
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.214

Financial Reports:

No articles found.

CinCor Pharma, Inc.

CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.